{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:24:31Z","timestamp":1775895871374,"version":"3.50.1"},"reference-count":38,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"unspecified","delay-in-days":150,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold>Japanese authorities have announced a plan to introduce a health technology assessment (HTA) system in 2016. This study assessed the potential impact of such a policy on the price of the antivirologic drug simeprevir.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>Taking the antivirologic drug simeprevir as an example, we compared the current Japanese price with hypothetical prices that might result if a U.K. (cost-utility) or German (efficiency frontier) style HTA assessment was in place.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>The simeprevir unit price under the current Japanese pricing scheme is 13,122 Japanese yen (equivalent to 109.35 U.S. dollars as of April 2015). Depending on the selection of comparators and the pricing method, and assuming that HTA will be used as a basis for price setting, the estimated prices of simeprevir vary up to four times higher than under the current Japanese pricing scheme.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold>Although the analysis is based on only one drug, it cannot be taken for granted that a new HTA system would reduce public healthcare expenditure in Japan.<\/jats:p>","DOI":"10.1017\/s0266462317000174","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T09:38:50Z","timestamp":1496223530000},"page":"121-127","source":"Crossref","is-referenced-by-count":11,"title":["A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR JAPAN? SIMULATING THE POTENTIAL IMPACT ON THE PRICE OF SIMEPREVIR"],"prefix":"10.1017","volume":"33","author":[{"given":"J\u00f6rg","family":"Mahlich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Kamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"S0266462317000174_ref021","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1048-z"},{"key":"S0266462317000174_ref025","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3041"},{"key":"#cr-split#-S0266462317000174_ref009.1","unstructured":"European Federation of Pharmaceutical Industries and Associations. 2015. Health Technology Assessment"},{"key":"#cr-split#-S0266462317000174_ref009.2","unstructured":"2. (HTA) application in select markets and implications for Japan, Tokyo. 2015."},{"key":"S0266462317000174_ref016","unstructured":"Cabinet Office Japan. Tables of GDP and its components. Tokyo: Cabinet Office Japan; 2015. http:\/\/www.esri.cao.go.jp\/en\/sna\/data\/sokuhou\/files\/2014\/qe144_2\/gdemenuea.html (accessed June 20, 2015)."},{"key":"S0266462317000174_ref006","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/gnr067"},{"key":"S0266462317000174_ref002","unstructured":"WHO. The World Health Report 2000: Health systems: Improving performance. Geneva: WHO; 2000"},{"key":"S0266462317000174_ref026","unstructured":"Gemeinsamer Bundesauschuss. Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V \u2013 Simeprevir. Berlin. 2015. https:\/\/www.g-ba.de\/downloads\/39-261-2098\/2014-11-20_AM-RL-XII_Simeprevir_2014-06-01-D-113_BAnz.pdf (accessed June 30, 2015)."},{"key":"S0266462317000174_ref027","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-014-0023-5"},{"key":"S0266462317000174_ref010","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.07.016"},{"key":"#cr-split#-S0266462317000174_ref001.1","unstructured":"6. Deloitte. Outlook life sciences 2015. Tokyo: Deloitte"},{"key":"#cr-split#-S0266462317000174_ref001.2","unstructured":"7. 2015. https:\/\/www2.deloitte.com\/content\/dam\/Deloitte\/global\/Documents\/Life-Sciences-Health-Care\/gx-lshc-2015-life-sciences-report-japan.pdf (accessed June 20, 2015)."},{"key":"S0266462317000174_ref003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60274-2"},{"key":"#cr-split#-S0266462317000174_ref007.1","unstructured":"8. OECD. Health Statistics 2014: How does Japan compare? Paris: OECD"},{"key":"#cr-split#-S0266462317000174_ref007.2","unstructured":"9. 2014. http:\/\/www.oecd.org\/els\/health-systems\/Briefing-Note-JAPAN-2014.pdf (accessed June 20, 2015)."},{"key":"S0266462317000174_ref015","unstructured":"WHO. Cost-effectiveness thresholds. Geneva: WHO; 2015. http:\/\/www.who.int\/choice\/costs\/CER_thresholds\/en\/ (accessed June 20, 2015)."},{"key":"S0266462317000174_ref029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.827"},{"key":"S0266462317000174_ref034","first-page":"941","article-title":"Uncertainty and the welfare economics of medical care","volume":"53","author":"Arrow","year":"1963","journal-title":"Am Econ Rev"},{"key":"S0266462317000174_ref014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02714.x"},{"key":"S0266462317000174_ref011","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.004"},{"key":"S0266462317000174_ref004","volume-title":"Reviews of health care quality: Japan - Raising standards","year":"2015"},{"key":"S0266462317000174_ref008","unstructured":"Kamae I . The new era of health technology assessment - A surge of new \u2018Black Ships\u2019. Canon Institute of Global Studies, Columns and Papers: Macroeconomics; 2016. http:\/\/www.canon-igs.org\/en\/column\/macroeconomics\/20160219_3517.html"},{"key":"S0266462317000174_ref024","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2014.868313"},{"key":"S0266462317000174_ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2012.12.005"},{"key":"S0266462317000174_ref018","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1029492"},{"key":"S0266462317000174_ref022","unstructured":"Ministry of Health Labour and Welfare. \u4e2d\u592e\u793e\u4f1a\u4fdd\u967a\u533b\u7642\u5354\u8b70\u4f1a (Central Social Insurance Medical Council). Tokyo: Ministry of Health Labour and Welfare; 2015. http:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-chuo.html?tid=128154, (accessed June 1st 2015)."},{"key":"S0266462317000174_ref028","doi-asserted-by":"publisher","DOI":"10.1007\/s40275-014-0007-4"},{"key":"S0266462317000174_ref033","unstructured":"Japan Pharmaceutical Manufacturers Association (JPMA). Pharmaceutical Administration and Regulations in Japan. Tokyo: JPMA; 2014. http:\/\/www.jpma.or.jp\/english\/parj\/whole.html (accessed May 20 2015)."},{"key":"S0266462317000174_ref005","doi-asserted-by":"crossref","DOI":"10.1596\/978-1-4648-0408-3","volume-title":"Universal health coverage for inclusive and sustainable development: Lessons from Japan","author":"Ikegami","year":"2014"},{"key":"S0266462317000174_ref031","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002032"},{"key":"S0266462317000174_ref032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.088"},{"key":"S0266462317000174_ref030","unstructured":"Ministry of Health Labour and Welfare. \u4e2d\u592e\u793e\u4f1a\u4fdd\u967a\u533b\u7642\u5354\u8b70\u4f1a (Central Social Insurance Medical Council). Tokyo: Ministry of Health Labour and Welfare; 2015. http:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000084737.html (accessed May 20 2015)."},{"key":"S0266462317000174_ref035","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.2316"},{"key":"S0266462317000174_ref020","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1629"},{"key":"S0266462317000174_ref017","unstructured":"Statistics Japan. Population statistics Japan. Tokyo: Statistics Japan; 2015. http:\/\/www.stat.go.jp\/english\/data\/jinsui\/tsuki\/index.htm (accessed May 20, 2015)."},{"key":"S0266462317000174_ref012","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12467"},{"key":"S0266462317000174_ref023","unstructured":"Ministry of Health Labour and Welfare. \u4e2d\u533b\u5354\u306e\u516c\u8868\u8cc7\u6599 (Central Social Insurance Medical Council official document), November 13. Tokyo: Ministry of Health Labour and Welfare; 2013."},{"key":"S0266462317000174_ref013","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21176"}],"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0266462317000174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T01:45:47Z","timestamp":1602207947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462317000174\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"alternative-id":["S0266462317000174"],"URL":"https:\/\/doi.org\/10.1017\/s0266462317000174","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}